BackgroundNo clinically proven effective antiviral strategy exists for the epidemic Coronavirus Disease 2019 . MethodsWe conducted a prospective, randomized, controlled, open-label multicenter trial involving adult patients with COVID-19. Patients were randomly assigned in a 1:1 ratio to receive conventional therapy plus Umifenovir (Arbidol) (200mg*3/day) or Favipiravir (1600mg*2/first day followed by 600mg*2/day) for 10 days. The primary outcome was clinical recovery rate of Day 7. Latency to relief for pyrexia and cough, the rate of auxiliary oxygen therapy (AOT) or noninvasive mechanical ventilation (NMV) were the secondary outcomes. Safety data were collected for 17 days.

Summary Background COVID-19 is an ongoing global pandemic. Changes in haematological characteristics in patients with COVID-19 are emerging as important features of the disease. We aimed to explore the haematological characteristics and related risk factors in patients with COVID-19. Methods This retrospective cohort study included patients with COVID-19 admitted to three designated sites of Wuhan Union Hospital (Wuhan, China). Demographic, clinical, laboratory, treatment, and outcome data were extracted from electronic medical records and compared between patients with moderate, severe, and critical disease (defined according to the diagnosis and treatment protocol for novel coronavirus pneumonia, trial version 7, published by the National Health Commission of China). We assessed the risk factors associated with critical illness and poor prognosis. Dynamic haematological and coagulation parameters were investigated with a linear mixed model, and coagulopathy screening with sepsis-induced coagulopathy and International Society of Thrombosis and Hemostasis overt disseminated intravascular coagulation scoring systems was applied. Findings Of 466 patients admitted to hospital from Jan 23 to Feb 23, 2020, 380 patients with COVID-19 were included in our study. The incidence of thrombocytopenia (platelet count <100 × 10 9 cells per L) in patients with critical disease (42 [49%] of 86) was significantly higher than in those with severe (20 [14%] of 145) or moderate (nine [6%] of 149) disease (p<0·0001). The numbers of lymphocytes and eosinophils were significantly lower in patients with critical disease than those with severe or moderate disease (p<0·0001), and prothrombin time, D-dimer, and fibrin degradation products significantly increased with increasing disease severity (p<0·0001). In multivariate analyses, death was associated with increased neutrophil to lymphocyte ratio (≥9·13; odds ratio [OR] 5·39 [95% CI 1·70–17·13], p=0·0042), thrombocytopenia (platelet count <100 × 10 9 per L; OR 8·33 [2·56–27·15], p=0·00045), prolonged prothrombin time (>16 s; OR 4·94 [1·50–16·25], p=0·0094), and increased D-dimer (>2 mg/L; OR 4·41 [1·06–18·30], p=0·041). Thrombotic and haemorrhagic events were common complications in patients who died (19 [35%] of 55). Sepsis-induced coagulopathy and International Society of Thrombosis and Hemostasis overt disseminated intravascular coagulation scores (assessed in 12 patients who survived and eight patients who died) increased over time in patients who died. The onset of sepsis-induced coagulopathy was typically before overt disseminated intravascular coagulation. Interpretation Rapid blood tests, including platelet count, prothrombin time, D-dimer, and neutrophil to lymphocyte ratio can help clinicians to assess severity and prognosis of patients with COVID-19. The sepsis-induced coagulopathy scoring system can be used fo...

We demonstrated in this paper the shape-controlled synthesis of hematite (alpha-Fe(2)O(3)) nanostructures with a gradient in the diameters (from less than 20 nm to larger than 300 nm) and surface areas (from 5.9 to 52.3 m(2)/g) through an improved synthetic strategy by adopting a high concentration of inorganic salts and high temperature in the synthesis systems to influence the final products of hematite nanostructures. The benefits of the present work also stem from the first report on the <20-nm-diameter and porous hematite nanorods, as well as a new facile strategy to the less-than-20-nm nanorods, because the less-than-20-nm diameter size meets the vital size domain for magnetization properties in hematite. Note that the porous and nonporous hematite one-dimensional nanostructures with diameter gradients give us the first opportunity to investigate the Morin temperature evolution of nanorod diameter and porosity. Evidently, the magnetic properties for nanorods exhibit differences compared with those for the spherical particle counterparts. Hematite nanorods are strongly dependent on their diameter size and porosity, where the magnetization is not sensitive to the size evolution from submicron particles to the 60-90 nm nanorods, while the magnetic properties change significantly in the case of <20 nm. In other words, for the magnetic properties of nanorods, in a comparable size range, the porous existence could also influence the magnetic behavior. Moreover, applications in formaldehyde (HCHO) gas sensors and lithium batteries for the hematite nanostructures with the diameter/surface area gradient reveal that the performance of electrochemical and gas-sensor properties strongly depends on the diameter size and Brunauer-Emmett-Teller (BET) surface areas, which is consistent with the crystalline point of view. Thus, this work not only provides the first example of the fabrication of hematite nanostructure sensors for detecting HCHO gas, but also reveals that the surface area or diameter size of hematite nanorods can also influence the lithium intercalation performances. These results give us a guideline for the study of the size-dependent properties for functional materials as well as further applications for magnetic materials, lithium-ion batteries, and gas sensors.

The reliability estimates for the Beck Depression Inventory (BDI) scores across studies were accumulated and summarized in a meta-analysis. Only 7.5% of the articles reviewed reported meaningful reliability estimates, indicating that the logic of “test score reliability” generally has not prevailed in clinical psychology regarding application of BDI. Analyses revealed that for BDI, the measurement error due to time sampling as captured by test-retest reliability estimate is considerably larger than the measurement error due to item heterogeneity and content sampling as captured by internal consistency reliability estimate. Also, reliability estimates involving substance addicts were consistently lower than reliability estimates involving normal subjects, possibly due to restriction of range problems. Correlation analyses revealed that standard errors of measurement (SEMs) were not correlated with reliability estimates but were substantially related to standard deviations of BDI scores, suggesting that SEMs should be considered in addition to reliability estimates when interpreting individual BDI scores.